Screener
Vertex Pharmaceuticals VRTX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Vertex Pharmaceuticals’s 8-K, filed August 3, 2026. Open the filing →
- Filed
- Aug 3, 2026, 4:09 PM EDT
- Accession
- 0000875320-26-000256
FAQ
- What is Vertex Pharmaceuticals's total current liabilities?
- Vertex Pharmaceuticals (VRTX) reported total current liabilities of $3.94B in Q2 2026.
- How has Vertex Pharmaceuticals's total current liabilities changed year-over-year?
- Vertex Pharmaceuticals's total current liabilities decreased by 4.8% year-over-year, from $4.14B to $3.94B.
- What is the long-term trend for Vertex Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's total current liabilities has grown at a 15.5% compound annual growth rate (CAGR), from $1.88B to $3.86B.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Vertex Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude